^
    Back
    Association details:
    Biomarker:AGR2 overexpression
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Hindawi
    Title:

    The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients

    Published date:
    09/16/2021
    Excerpt:
    This study was conducted on 224 ER-positive breast cancer patients...group 1 was tamoxifen sensitive and groups 2 and 3 were tamoxifen resistant...SOX2 and AGR2 biomarkers expression and serum AGR2 level were significantly higher in groups 2 and 3 in comparison to group 1...
    DOI:
    https://doi.org/10.1155/2021/9947540
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Dis Markers
    Title:

    AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients

    Published date:
    09/03/2013
    Excerpt:
    As shown by our experimental and clinical evaluations, elevated AGR2 expression predicts decreased efficacy of tamoxifen treatment. From this perspective, AGR2 is a potential predictive biomarker enabling selection of an optimal algorithm for adjuvant hormonal therapy in postmenopausal ER-positive breast cancer patients.
    DOI:
    10.1155/2013/761537